

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1 (currently amended): A modified anti-viral peptide ~~comprising consisting of~~ [[:]] a peptide ~~that has been modified to contain a succinimidyl or maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds, said peptide consisting of an~~ [[the]] amino acid sequence ~~of which is~~ selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, ~~and that exhibits~~ ~~said sequence exhibiting an~~ anti-viral activity against human immunodeficiency virus (HIV) ~~and a succinimidyl or maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.~~

Claim 2 (canceled).

Claim 3 (previously presented): The modified peptide of claim 1 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 4 (previously presented): The modified peptide of claim 1 wherein said peptide is DP 178, the amino acid sequence of which is SEQ ID NO:1.

Claim 5 (canceled).

Claim 6 (previously presented): The modified peptide of claim 1 wherein said peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4,

SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claims 7-18 (previously canceled).

Claim 19 (currently amended): A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, a modified peptide consisting of a peptide that has been modified to contain a succinimidyl or maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds, said peptide consisting of an [[the]] amino acid sequence of which is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, and that exhibits said sequence exhibiting an anti-viral activity against human immunodeficiency virus (HIV) modified with a succinimidyl or maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds, in a physiologically acceptable medium.

Claim 20 (previously presented): The composition of claim 19 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 21 (previously presented): The composition of claim 20 wherein said peptide is DP 178, the amino acid sequence of which is SEQ ID NO:1.

Claims 22-30 (canceled).

Claim 31 (previously presented): The composition of claim 19 wherein said peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claim 32 (withdrawn): A conjugated peptide comprising the modified anti-viral peptide of claim 1 covalently bonded to a blood component.

Claim 33 (withdrawn): The conjugated peptide of claim 32 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 34 (withdrawn): The conjugated peptide of claim 32, wherein said modified anti-viral peptide has the amino acid sequence of SEQ ID NO:1.

Claim 35 (withdrawn): The conjugated peptide of claim 32, wherein said modified anti-viral peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claim 36 (previously presented): A composition comprising the modified anti-viral peptide of claim 1 in a physiologically acceptable medium.

Claim 37 (previously presented): The composition of claim 36 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 38 (previously presented): The composition of claim 36 wherein said modified anti-viral peptide has the amino acid sequence of SEQ ID NO:1.

Claim 39 (previously presented): The composition of claim 36 wherein said modified anti-viral peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claim 40 (withdrawn -- currently amended): A composition comprising the conjugated peptide of claim 31 32 in a physiologically acceptable medium.

Claim 41 (withdrawn): The composition of claim 40 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

Claim 42 (withdrawn): The composition of claim 40 wherein said modified anti-viral peptide has the amino acid sequence of SEQ ID NO:1.

Claim 43 (withdrawn): The composition of claim 40 wherein said modified anti-viral peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.


Claims 44-51 (Cancelled).

Claim 52 (previously presented): The modified anti-viral peptide of claim 1 having the formula:




((SEQ ID NO:1)-Lys-(ϵ -MPA)).

Claim 53 (previously presented): The composition of claim 19 comprising the modified peptide formula:




((SEQ ID NO:1)-Lys-(ϵ -MPA)).

Claim 54 (previously presented): The conjugated peptide of claim 32 comprising the modified peptide formula:



((SEQ ID NO:1)-Lys-(ϵ -MPA)).

Claim 55 (previously presented): The composition of claim 36 comprising the modified peptide formula:



((SEQ ID NO:1)-Lys-(ϵ -MPA)).

Claim 56 (withdrawn): The composition of claim 40 wherein the conjugated peptide comprises the modified peptide of formula:



((SEQ ID NO:1)-Lys-(ϵ -MPA)).

Claims 57-58 (cancelled)